Can Peptides Be Detected in Drug Tests?

Can peptides be detected in drug tests?

The short answer is that it depends entirely on which test is being run. Anti-doping testing used in competitive sport is specifically designed to detect many peptide classes, and several of those classes sit on the World Anti-Doping Agency (WADA) Prohibited List. The standard drug screens used in Australian workplaces and at the roadside are a different kind of test altogether, built around a defined list of recreational drugs of abuse and governed by the panel and the testing body in use.

So the honest regulatory picture has two separate worlds. In elite and competitive sport, a dedicated anti-doping sample can be analysed for peptide hormones, growth hormone secretagogues and certain non-approved compounds. Ordinary workplace and roadside screens are designed and administered for an entirely different purpose. This article explains both landscapes neutrally so that researchers and athletes understand the rules. It is educational only and is not guidance to avoid, time or defeat any test.

How the WADA Prohibited List classifies peptides

WADA publishes an annual Prohibited List that defines which substances and methods are banned in sport. Peptides do not sit in a single bucket. They are scattered across different classes depending on their chemistry and regulatory approval status, and two classes matter most for the compounds researchers ask about.

A key distinction on the List is in-competition versus out-of-competition. Some classes are prohibited only in competition, while others are prohibited at all times, meaning an athlete can be tested for them during the off-season as well. The two peptide-relevant classes discussed below, S0 and S2, are both prohibited at all times.

• Class S0, Non-approved Substances: pharmacological substances not covered elsewhere on the List and with no current approval by any government health authority for human therapeutic use.
• Class S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics: includes growth hormone, its releasing factors and secretagogues, and related peptides.

BPC-157 and the S0 non-approved class

BPC-157 is one of the most searched research peptides in Australia, and its anti-doping status is clear. WADA added BPC-157 to the Prohibited List under class S0, effective 1 January 2022, following publication of the 2022 List on 1 October 2021. It has remained listed on subsequent editions.

Class S0 captures substances that have no current approval from any government health regulator for human therapeutic use and are not addressed by another section of the List. Compounds in this class are prohibited at all times, both in and out of competition. For athletes bound by anti-doping rules, that means BPC-157 is banned year round. For a wider look at where BPC-157 sits under Australian law, see the linked guide below.

is BPC-157 legal in Australia

Growth hormone secretagogues, GHRPs and GHRH analogues (S2)

A large group of commonly discussed peptides falls under class S2. This section covers growth hormone itself and the compounds that act on the growth hormone axis. Because they relate to a peptide hormone pathway, they are prohibited at all times under WADA rules.

WADA groups several familiar research compounds here. Growth hormone releasing peptides (GHRPs) and ghrelin mimetics, and growth hormone releasing hormone (GHRH) analogues, are named as examples of the class.

• GHRH analogues such as CJC-1295, sermorelin and tesamorelin.
• Growth hormone releasing peptides and ghrelin mimetics such as ipamorelin, hexarelin and GHRP-2 and GHRP-6.
• Growth hormone itself and its releasing factors.

is CJC-1295 legal in Australia

GLP-1 analogues and the WADA Monitoring Program

Not every peptide class is prohibited. GLP-1 receptor analogues such as semaglutide and tirzepatide are currently permitted in sport and are not on the Prohibited List. Instead, WADA has placed them on its Monitoring Program, which tracks patterns of use without banning the substance.

Semaglutide was introduced to the Monitoring Program in 2024, and tirzepatide was added to monitoring effective 1 January 2026. WADA's expert group has stated there is currently insufficient evidence that these compounds meet the criteria for inclusion on the Prohibited List, and their permitted status was carried into the 2027 List. The Monitoring Program is worth watching, because substances placed under monitoring have in the past later moved onto the List as evidence accumulates. Anyone bound by anti-doping rules should always check the current year's official WADA List rather than relying on a summary.

How anti-doping laboratories test for peptides

When a sample does go to a WADA-accredited anti-doping laboratory, the analytical methods are far more sophisticated than a basic screen. This section describes those methods at a neutral, educational level. It is not evasion guidance and contains no detection windows or timing information.

Laboratories commonly rely on mass spectrometry, often coupled with liquid chromatography (LC-MS/MS or high-resolution mass spectrometry), to identify many peptides and their metabolites directly. Growth hormone presents a harder analytical problem because it is also produced naturally by the body, so dedicated approaches are used.

• Mass spectrometry based methods that identify a peptide or its breakdown products by mass.
• Immunoassay based approaches, including isoform differential tests that compare forms of a hormone.
• Biomarker based tests that look at markers such as IGF-1 and procollagen fragments rather than the hormone itself.
• The Athlete Biological Passport, which tracks an athlete's own biological markers over time to flag unusual variation.

Standard workplace and roadside drug tests

The tests most people actually encounter are very different from anti-doping analysis. Standard Australian workplace urine or oral-fluid screens, and roadside drug tests, are designed around recreational drugs of abuse. The common 5-panel and 10-panel formats target substances such as cannabis (THC), cocaine, opioids, amphetamines and related stimulants, and the Australian standards that govern these screens are written around those categories.

These panels generally use immunoassay technology, which relies on antibodies tuned to a defined set of drug-of-abuse molecules. The scope of any particular test is set by the panel that is chosen and the organisation that commissions it, and testing formats and requirements vary between workplaces and change over time. For that reason, anyone who is subject to a specific testing requirement should direct their questions to the relevant testing authority or the body that administers the test, rather than relying on a general article. This section is neutral background on what these tests are designed to screen for, not advice about any individual compound.

Australian regulatory context

Separate from sport testing, Australia regulates these compounds through the Therapeutic Goods Administration (TGA) and the Poisons Standard, which schedules substances and governs how they may be supplied. Many research peptides are not approved therapeutic goods and are handled as laboratory research chemicals rather than consumer products.

The products discussed on this site are research-use-only laboratory compounds and are framed accordingly. If you are researching how specific classes are positioned in Australia, or how to confirm what you are working with, the resources below provide further regulatory background.

research peptides Australia buyers guide verify peptide batch public register